The aim is to study the prognosis of breast cancer in fertile age women with new approaches. Today breast cancer is the most common oncological disease among fertile age women in the world and it is running at 6% of all cancers in this group of women. The very young patients are attended to more unfavorable prognostic features in the tumor: they have more widespread tumors, metastasizing tumors which are characterized by a high-grade tumor and more often with no express of estrogen and progesterone receptors.
Our study included 130 active fertile age women with breast cancer. All patients were diagnosed the initial stage T1-2 I0 M0. Of these, 17% were women aged 26-30 years, 33% were 31-35 year- old- women, 50% were women at the age of 36-40 years.
According to study results survival at ER(+) and PR(+) was respectively: 97.3%, 94.6%. At negative ER(-) and PR(-) survival rate was respectively 65.4%, 68.7%. When ER positive(+) and negative ER(-), respectively, the survival was 81.5%, 79.3%. At negative ER(-) and positive PR(+), the survival was 90.4%, 88.5%, respectively. In HER2/neu negative patient survival rates were 96.2%, 92.2%, respectively. In group of patients with HER2/neu(2+) expression level these figures were 45.1%, 40.2%. In group of patients with HER2/neu(3+) expression level these rates were 34.3%, 29.4%. When three negative prognosis ER(-), PR(-), HER2/neu-, survival rates were 19.5%, 15.3%, respectively. In the study of tumor morphology 58% of patients were diagnosed with infiltrating ductal carcinoma, 31% of patients were diagnosed with infiltrative lobular carcinoma and 7% of patients were diagnosed with Paget cancer and 4% of patients were revealed rare types of cancer.
Thus, the presence of steroid hormone receptors in breast tumor tissues as well as the absence of oncoprotein HER2/neu correlates with higher 5-year overall and relapse-free survival rates. The absence of steroid hormone receptors, as well as HER2/neu hyper expression in malignant breast tissues, significantly decrease the ratio of 5-year overall and relapse-free survival. The most unfavorable factor for active fertile age patients in terms of prognosis are tumors with ER(-), PR(-), HER2/neu-.
Clinical trial identification
All authors have declared no conflicts of interest.